Selvin Elizabeth, Ali Mohammed K
Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Hubert Department of Global Health and Department of Epidemiology, Rollins School of Public Health, and Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, GA.
Diabetes Care. 2017 Sep;40(9):1139-1143. doi: 10.2337/dc16-2442.
National surveillance data show a sustained decline in the incidence rate of diagnosed diabetes, which has been heralded as a success in the battle against diabetes in the U.S. In this Perspective, we take a closer look at these data and provide additional insights to help interpret these trends. We examine multiple sources of data on the prevalence and incidence of diabetes in the U.S. as well as data on trends in diabetes risk factors to provide context for these national surveillance findings. Although some of the incidence decline may represent real progress against diabetes, it is likely that there are also nonbiological factors at play, especially changes in diagnostic criteria for diabetes. We present and discuss data that suggest improved detection and changes in screening and diagnostic practices may have resulted in the depletion of the "susceptible population." Providing this context for the recent declines in new diabetes diagnoses observed in national data is critical to help avoid misinterpretation. We argue that it is premature to declare victory against the epidemic of diabetes in the U.S. and discuss how we might better focus current public health efforts, including a specific emphasis to address prediabetes.
国家监测数据显示,确诊糖尿病的发病率持续下降,这在美国抗击糖尿病的斗争中被誉为一项成功。在这篇观点文章中,我们仔细研究了这些数据,并提供更多见解以帮助解读这些趋势。我们审视了美国糖尿病患病率和发病率的多种数据来源,以及糖尿病风险因素趋势的数据,以为这些国家监测结果提供背景信息。虽然发病率的一些下降可能代表着在抗击糖尿病方面取得了实际进展,但很可能也有非生物学因素在起作用,尤其是糖尿病诊断标准的变化。我们展示并讨论了一些数据,这些数据表明检测的改善以及筛查和诊断实践的变化可能导致了“易感人群”的减少。为国家数据中近期新诊断糖尿病病例的下降提供这一背景信息,对于避免误解至关重要。我们认为现在宣称在美国战胜糖尿病流行还为时过早,并讨论了我们如何能更好地聚焦当前的公共卫生工作,包括特别强调应对糖尿病前期。